MARKET

BNGO

BNGO

Bionano Genomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5268
-0.0112
-2.08%
After Hours: 0.5450 +0.0182 +3.45% 19:47 06/05 EDT
OPEN
0.5600
PREV CLOSE
0.5380
HIGH
0.5600
LOW
0.5025
VOLUME
9.16M
TURNOVER
--
52 WEEK HIGH
4.700
52 WEEK LOW
0.2500
MARKET CAP
19.89M
P/E (TTM)
-0.2247
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BNGO stock price target is 1.833 with a high estimate of 3.000 and a low estimate of 1.000.

EPS

BNGO News

More
What Makes Bionano Genomics, Inc. (BNGO) a New Strong Buy Stock
Zacks · 05/28 17:00
Bionano up on positive data on optical mapping technology
In an online presentation hosted by the Cancer Genomics Consortium on May 12, Dr. Brynn Levy from Columbia University and Dr. Rashmi Kanagal-Shamanna from
seekingalpha · 05/19 17:58
Bionano Genomics Shares Spike To Session High, Up 9%, Amid US PTO Abstract For 'Integrated analysis devices and related fabrication methods and analysis techniques'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=10654715&OS=10654715&RS=10654715
Benzinga · 05/19 15:00
Cancer Genomics Consortium Members Demonstrate 100% Concordance Between Bionano Saphyr and Gold Standard Cytogenetics in Leukemia
GlobeNewswire · 05/19 13:00
Bionano Genomics to Report First Quarter 2020 Financial Results on June 18, 2020
GlobeNewswire · 05/14 21:30
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers IsoRay, Inc. (NYSE: ISR) shares rose 56.3% to $1.25 in pre-market trading after the company reported Q3 results. The Centers for Medicare and Medicaid Services also approved Isoray's application for billing codes for the intraoperative use of Cesiu
Benzinga · 05/13 11:17
Bionano Genomics Adds Healthcare and Genomics Industry Experts with Experience in Commercialization and Reimbursement to Its Board of Directors
GlobeNewswire · 05/04 22:00
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's Why
Zacks · 04/23 17:00

Industry

Advanced Medical Equipment & Technology
+2.45%
Healthcare Equipment & Supplies
+2.76%

Hot Stocks

Symbol
Price
%Change

About BNGO

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Sequencing alone, however, is significantly limited due to its inability to reveal structural variations. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response.
More

Webull offers kinds of BioNano Genomics Inc stock information, including NASDAQ:BNGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNGO stock news, and many more online research tools to help you make informed decisions.